NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LCTX

Lineage Cell Therapeutics Inc

Jun 30 • 04:00PM ET

0.9074

Dollar change -0.0278
Percentage change -2.97	%

Healthcare • Biotechnology • USA • AMEX

Peers: FATE VCEL TVRD MDXG STEM MESO MRKR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	0.44%	Shs Outstand	228.36M	Perf Week	-5.42%
Market Cap	207.21M	Forward P/E	-	EPS next Y	-0.05	Insider Trans	-	Shs Float	227.36M	Perf Month	32.27%
Enterprise Value	160.17M	PEG	-	EPS next Q	-0.03	Inst Own	48.65%	Short Float	12.64%	Perf Quarter	84.47%
Income	-16.21M	P/S	21.67	EPS this Y	-9.73%	Inst Trans	-8.38%	Short Ratio	13.88	Perf Half Y	68.66%
Sales	9.56M	P/B	2.62	EPS next Y	49.86%	ROA	-14.72%	Short Interest	28.73M	Perf YTD	80.58%
Book/sh	0.35	P/C	4.33	EPS next 5Y	9.01%	ROE	-21.40%	52W High	1.15 -21.10%	Perf Year	0.82%
Cash/sh	0.21	P/FCF	-	EPS past 3/5Y	29.15% -2.93%	ROIC	-20.23%	52W Low	0.37 148.53%	Perf 3Y	-32.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	34.59% 45.08%	Gross Margin	90.90%	Volatility	15.35% 11.07%	Perf 5Y	-5.47%
Dividend TTM	-	EV/Sales	16.75	EPS Y/Y TTM	40.83%	Oper. Margin	-223.10%	ATR (14)	0.10	Perf 10Y	-69.07%
Dividend Ex-Date	-	Quick Ratio	3.82	Sales Y/Y TTM	19.42%	Profit Margin	-169.57%	RSI (14)	60.69	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	3.82	EPS Q/Q	48.88%	SMA20	9.89%	Beta	1.61	Target Price	3.92
Payout	-	Debt/Eq	0.03	Sales Q/Q	4.02%	SMA50	43.07%	Rel Volume	3.47	Prev Close	0.94
Employees	77	LT Debt/Eq	0.01	Earnings	May 13 AMC	SMA200	37.90%	Avg Volume	2.07M	Price	0.91
IPO	Mar 05, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.18% -12.67%	Trades		Volume	7,188,749	Change	-2.97%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Initiated	Craig Hallum	Buy	$4
Nov-02-22	Initiated	Robert W. Baird	Outperform	$5
Jun-14-22	Initiated	B. Riley Securities	Buy	$4
Aug-19-21	Initiated	Noble Capital Markets	Outperform	$8
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight	$6

Jun-23-25 07:00AM	OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025 (Business Wire)
Jun-05-25 08:00AM	Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium (Business Wire)
May-14-25 11:39AM	Q1 2025 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC (Business Wire)
03:14AM	Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
05:10PM	Loading…
May-13-25 05:10PM	Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-12-25 05:45PM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.89%
08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 (Business Wire)
May-01-25 08:00AM	Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (Business Wire)
Apr-22-25 08:00AM	Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium (Business Wire) +7.45%
Apr-21-25 08:00AM	Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) (Business Wire)
Mar-11-25 11:12AM	Q4 2024 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-10-25 05:25PM	Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-05-25 08:00AM	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 (Business Wire)
Feb-12-25 05:37AM	Lineage begins study of OPC1 delivering device for spinal cord injury treatment (Medical Device Network)
Feb-11-25 08:00AM	Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury (Business Wire)
Feb-04-25 08:00AM	Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference (Business Wire)
Jan-30-25 12:00PM	Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jan-27-25 04:05PM	Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering (Business Wire)
Jan-06-25 08:00AM	Lineage Cell Therapeutics Issues Letter to Stockholders (Business Wire) -6.90%
Jan-04-25 08:10AM	Lineage Cell price target lowered to $2 from $3 at D. Boral Capital (TipRanks)
Dec-17-24 09:35AM	Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround (Zacks)
Dec-03-24 02:55AM	Is Lineage (LINE) the Best New Pick in Brad Gerstners Portfolio? (Insider Monkey) -7.10%
Nov-21-24 05:00PM	Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering (Business Wire) -6.45% -16.02%
09:35AM	Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-20-24 08:00AM	Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering (Business Wire) -28.99%
Nov-15-24 04:00PM	Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
05:15PM	Loading…
Nov-14-24 05:15PM	Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-07-24 08:00AM	Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 (Business Wire)
Oct-14-24 08:00AM	Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit (Business Wire)
Oct-09-24 05:52PM	Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ... (GuruFocus.com)
12:00PM	What Makes Lineage Cell (LCTX) a New Buy Stock (Zacks)
Sep-25-24 08:00AM	OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium (Business Wire)
Sep-18-24 08:00AM	Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance, at the 59th Annual Inner Ear Biology Workshop (Business Wire)
Aug-13-24 08:00AM	Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (Business Wire)
Aug-08-24 06:35PM	Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Aug-01-24 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire) -6.40%
Jul-02-24 08:00AM	Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index (Business Wire)
May-30-24 08:00AM	Lineage to Present at 2024 BIO International Convention (Business Wire) +6.32%
May-21-24 08:00AM	Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium (Business Wire)
May-10-24 04:40PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.84%
03:49PM	Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines (GuruFocus.com)
02:09PM	Q1 2024 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 04:01PM	Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-06-24 08:00AM	OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit (Business Wire) +22.64%
May-02-24 08:00AM	Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (Business Wire) -7.08%
Apr-30-24 08:00AM	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Business Wire)
Apr-29-24 04:30PM	Lineage Announces Changes to Board of Directors (Business Wire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-01-24 08:00AM	Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development (Business Wire)
Mar-18-24 10:31AM	15 Best Anti-Aging Foods for Youthful Skin (Insider Monkey) -9.30%
08:00AM	Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium (Business Wire)
Mar-14-24 03:53PM	Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-13-24 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit (Business Wire)
Mar-11-24 08:00AM	RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting (Business Wire)
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +15.04%
Mar-07-24 10:36PM	Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-29-24 08:00AM	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 (Business Wire)
Feb-13-24 08:00AM	Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury (Business Wire) -5.56%
Feb-09-24 09:15AM	Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering (Business Wire)
Feb-06-24 09:15AM	Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering (Business Wire) +6.73%
Jan-16-24 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS (Business Wire)
Dec-18-23 08:00AM	Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury (Business Wire) +16.47%
Nov-11-23 04:02PM	3 Penny Stocks to Buy for the Next Bull Run (InvestorPlace)
Nov-10-23 02:13PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:17AM	Q3 2023 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:01PM	Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-01-23 08:00AM	Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023 (Business Wire)
Oct-24-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting (Business Wire)
Oct-17-23 05:14PM	Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks (InvestorPlace)
Oct-11-23 08:00AM	Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells (Business Wire)
Oct-05-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire) +10.00%
Sep-19-23 08:00AM	Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 (Business Wire)
Sep-13-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress (Business Wire)
Sep-11-23 08:00AM	Lineage to Present at 2023 International Spinal Research Trust Network Meeting (Business Wire)
Sep-06-23 09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics (Business Wire)
Aug-29-23 08:00AM	Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference (Business Wire)
Aug-13-23 06:39AM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 09:43AM	Q2 2023 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:15PM	Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Aug-09-23 08:50AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-08-23 06:40PM	U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates (Zacks)
Aug-03-23 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (Business Wire)
Jul-24-23 08:00AM	Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer (Business Wire)
May-22-23 08:00AM	Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index (Business Wire)
May-16-23 12:02PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 05:35PM	Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-09-23 08:00AM	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Business Wire)
May-04-23 06:15PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (Business Wire)
Apr-26-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire)

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	Director	Jan 27 '25	Buy	0.76	7,894,737	6,000,000	49,560,992	Jan 28 07:49 PM
Howe Jill Ann	Chief Financial Officer	Nov 26 '24	Buy	0.59	15,000	8,850	25,500	Nov 26 04:58 PM
Samuel George A. III	General Counsel	Nov 26 '24	Buy	0.60	15,000	9,000	22,184	Nov 26 04:55 PM
Mulroy Michael H.	Director	Nov 22 '24	Buy	0.57	40,000	22,640	298,555	Nov 25 04:30 PM
Culley Brian M	President and CEO	Nov 21 '24	Buy	0.60	40,000	24,000	194,842	Nov 22 09:00 AM
Howe Jill Ann	Chief Financial Officer	Aug 16 '24	Buy	0.89	10,500	9,345	10,500	Aug 19 06:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LCTX

Lineage Cell Therapeutics Inc

Upgrade your FINVIZ experience